BCA
ARQT icon

Berman Capital Advisors’s Arcutis Biotherapeutics ARQT Stock Holding History

Berman Capital Advisors’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$1K Buy
+83
New +$1.89K ﹤0.01% 1799

Other funds holding ARQT

FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Berman Capital Advisors's ARQT Position: Q3 2021 in Review

Berman Capital Advisors opened a new position in Arcutis Biotherapeutics (ARQT) in Q3 2021: 83 shares worth $1K. The stake represents ﹤0.01% of the portfolio and ranks #1799 among its holdings.

103 funds tracked by Wall St. Rank hold ARQT as of Q3 2021.

  • Berman Capital Advisors held 83 shares of Arcutis Biotherapeutics worth $1K as of Q3 2021.
  • Arcutis Biotherapeutics was a new Berman Capital Advisors position in Q3 2021.
  • Arcutis Biotherapeutics made up ﹤0.01% of Berman Capital Advisors's portfolio in Q3 2021, its #1799 holding.
  • 103 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q3 2021.

Based on Berman Capital Advisors's 13F filing for Q3 2021, filed 7 Oct 2021.